Two Seas Capital LP Buys New Position in uniQure N.V. $QURE

Two Seas Capital LP bought a new stake in shares of uniQure N.V. (NASDAQ:QURE) in the third quarter, Holdings Channel.com reports. The fund bought 1,324,022 shares of the biotechnology company’s stock, valued at approximately $31,988,000. uniQure accounts for 0.4% of Two Seas Capital LP’s investment portfolio, making the stock its 23rd biggest position.

Several other hedge funds have also recently added to or reduced their stakes in QURE. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the period. Orbimed Advisors LLC lifted its holdings in uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after buying an additional 1,398,749 shares during the period. Siren L.L.C. bought a new stake in uniQure during the first quarter valued at $16,350,000. Fiera Capital Corp bought a new stake in uniQure during the fourth quarter valued at $18,390,000. Finally, SG Americas Securities LLC grew its holdings in uniQure by 1,107.3% during the 1st quarter. SG Americas Securities LLC now owns 776,604 shares of the biotechnology company’s stock worth $12,697,000 after acquiring an additional 712,278 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Up 1.1%

Shares of QURE stock traded up $0.26 on Tuesday, reaching $23.06. 2,823,008 shares of the company were exchanged, compared to its average volume of 2,468,617. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -5.75 and a beta of 1.06. The company has a 50-day moving average of $42.99 and a 200-day moving average of $33.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period in the previous year, the firm earned ($0.69) earnings per share. Analysts anticipate that uniQure N.V. will post -3.82 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on QURE. HC Wainwright reissued a “buy” rating on shares of uniQure in a research report on Tuesday, September 29th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 target price on shares of uniQure in a research note on Tuesday, September 29th. Leerink Partners lifted their target price on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Finally, Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.73.

uniQure Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.